Aug 20 (Reuters) - Hikma Pharmaceuticals Plc reported a 44 percent rise in first-half adjusted profit, helpedby strong demand for its high-margin injectibles particularly inthe United States.
Adjusted profit attributable to shareholders rose to $176million in the six months ended June 30 from $122 million a yearearlier.
Revenue at the Jordanian company, which makes and marketsbranded and non-branded generics and injectibles, rose 16percent to $738 million.
Revenue rose 41 percent to $346 million at Hikma'sinjectibles business, accounting for 47 percent of total sales. (Reporting by Roshni Menon in Bangalore; Editing by GopakumarWarrier)
Hikma Pharmaceuticals (HIK)
